Immunome Q1 2026 net loss $53.8M; NDA filed for varegacestat; cash $582.7M

Immunome Inc.

2026-Q1 EPS reported -$0.48

Net loss of $53.8M; R&D expenses $46.4M (incl. $3.7M stock comp); G&A $13.0M (incl. $4.2M stock comp).
Cash and equivalents $582.7M at March 31, 2026; expected to fund operations into 2028.
NDA submitted to FDA in April 2026 for varegacestat for desmoid tumors; Phase 3 RINGSIDE data selected for oral presentation at ASCO 2026.
Phase 1 trial of IM-1021 ongoing with objective responses in B-cell lymphoma; initial lymphoma data expected in 2026.
IND clearance for IM-1617 (first-in-class ADC) in April 2026; INDs for IM-1340 and IM-1335 planned mid/late 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Immunome Inc. reported the quarter ended March 31, 2026 results: net income net loss of $53.8 million.

Period: the quarter ended March 31, 2026
Net income: net loss of $53.8 million
Result: reported results

Exact text from the filing

Immunome reported a net loss of $53.8 million for the quarter ended March 31, 2026.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-219367

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.